Q-omics provides the consensus-scored HTR1E profile across patient tissues and cancer cell-line models. HTR1E expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, HTR1E is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, HTR1E RNA expression shows 12,410 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCEC, THCA, and GBM as cancer lineages where HTR1E shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HTR1E — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HTR1E survival associations across molecular data types. HTR1E RNA expression shows survival associations in the most cancer types (11), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HTR1E RNA expression–survival associations across cancer types. High HTR1E expression shows unfavorable associations in UCEC, CHOL, ACC and HNSC, but favorable associations in KICH and LGG. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UCEC as the clearest survival context for HTR1E RNA expression.
This table summarizes HTR1E tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for HTR1E. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HTR1E shows lower tumor expression in THCA, STAD, KIRC, UCEC and PRAD and higher tumor expression in BRCA. The THCA box plot shows higher HTR1E RNA expression in normal versus tumor tissue (log2 FC = −1.335, t-test p < 0.001).
This table shows molecular features associated with HTR1E in patient tissues and cancer cell lines. In patient samples, HTR1E shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, HTR1E RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BONE.
